InsidersTradesSigma
Track the Glenmark Pharmaceuticals Limited share price and the full insider trade history of the company, a listed equity based in India. Shares are listed on the IN market, under the supervision of SEBI (PIT + SAST). Operating in the Health Care sector, Glenmark Pharmaceuticals Limited has recorded 13 reports. Market capitalisation: €631.7bn. The latest transaction was disclosed on 22 September 2023 (Sale). Among the most active insiders: Glenn Mario Saldanha. Every trade is free.
13
Insider Decl.
n/a
Thresholds
€203,926
7 ops.
Buy Volume
€27,554
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Glenmark Pharmaceuticals Limited Buy (bullish), based on 11 analysts. Average price target: ₹2,497.27.
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,941 of 29,064 companies
59.4
score / 100
Value41
Quality78
FCF yld3.3%
Earn yld2.2%
EV/EBITDA23.0x
ROE14%
Gross mgn72%
Net mgn8.1%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 September 2023
Declarations13 total
1,000 shares@ ₹852.0040.0% of flowEquity SharesSEBI:7c43f029fcf65d701002d87cbc38f4b76c05691e
1,000 shares@ ₹852.0040.0% of flowEquity SharesSEBI:4735f3b198350556570238ed4d2ffa4d36737a5f
500 shares@ ₹851.0220.0% of flowEquity SharesSEBI:e66100d169abd1b49336835c9bcfd5956cdd6833
250 shares@ ₹490.192100.0% of flowEquity SharesSEBI:a283ff59f1d01e5f26fe4c410f3339b8dd4e629e
559 shares@ ₹535.6834100.0% of flowEquity SharesSEBI:ad6a757c300c502fcdefcf162081d13e883d157f
20,000 sharesEquity SharesSEBI:e06c089566a41c4b5ee160b60fbae8e1e10c0e7b
10,000 sharesEquity SharesSEBI:a1e94610183e8e27382d484204aff805092b4751
10,000 sharesEquity SharesSEBI:1511c0d568f366fa2576ec8a989296183f4d31d3
9,800 shares@ ₹513.015230.4% of flowEquity SharesSEBI:32da8d7c912f1d4d9db504832ae09f596a698347
1,950 shares@ ₹512.8651100.0% of flowEquity SharesSEBI:da3603681fcec6d45c53b1c6d36c6d3f53bdf9e4
7,800 shares@ ₹640.000.0000% mcap42.4% of flowEquity SharesSEBI:fe9844636b32f99c393cfd6c43b8d98c8ab54355
2,800 shares@ ₹641.85610.0000% mcap15.2% of flowEquity SharesSEBI:8de2ea524f0611f5960938f5b20074c58d0281b6
7,870 shares@ ₹636.84160.0000% mcap42.4% of flowEquity SharesSEBI:cbe4bc773724e8e0f53f03e1d6508c57011868b5
13 of 13 declarations
关于 Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited 是一家印度制药公司，专注于仿制药和品牌产品的研究、开发和制造。该公司在孟买证券交易所上市。